Janssen Search
Search results
Oral Cavity Oropharyngeal Cancer
Partnership to Intercept Oral Cavity/Oropharyngeal Cancer The Disease Interception Accelerator established a partnership with UbiVac, a privately held, clinical-stage, immuno-oncology company for the development of an immunotherapy that is intended to ...
Commercialization of Our Medicines
Commercialization: Ensuring the Reach of Our Medicines to Patient Populations on a Global Scale “I’m deeply inspired by the legacy of this team, which for more than two decades has been a world leader in the development of transformational medicines, ...
Tumor Immunoenvironment
Apr 02, 2015 Evolving Tumor Microenvironment Strategy Our evolving strategy centers on innovative approaches to drug development based on a deep understanding of the critical relationships between cancer cells and the tumor microenvironment, * with ...
Silvia S. Chen, Ph.D.
SILVIA S. CHEN, PH.D. HEAD OF CHINA LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON AND WORLD WITHOUT DISEASE ACCELERATOR As Head of China for the Lung Cancer Initiative (LCI) at Johnson & Johnson (J&J) and the World Without Disease Accelerator ...
Access and Pricing Principles
Medicines can only help if people can get them. Every step of our journey means nothing if our medicine does not reach its final destination. We help navigate increasingly complex healthcare systems and continue to work to enable local patient access to ...
Janssen Demonstrates Commitment to Transform the Treatment of Multiple Myeloma through Innovative Science and Industry-Leading Portfolio with Largest-Ever Presence at 20th International Myeloma Society Annual Meeting
Sep 27, 2023 United States Presentations to highlight latest data across biologic, bispecific and CAR-T therapies with added insights from Global Multiple Myeloma Call-to-Action RARITAN, N.J., September 27, 2023 — The Janssen Pharmaceutical Companies ...
Lung Cancer Awareness Month
November is Lung Cancer Awareness Month, a time to raise awareness of the need for more research and better community awareness of this disease. Learn more about our focus here. Event Date: Sunday, November 1, 2020- 14:00 Event End Date: Sunday, ...
Lung Cancer Awareness Month
November is Lung Cancer Awareness Month, a time to raise awareness of the need for more research and better community awareness of this disease. Learn more about our focus here. Event Date: Monday, November 1, 2021- 15:30 Event End Date: Monday, ...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
Aug 20, 2024 United States RYBREVANT ® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT ...
Tumor Microenvironment in Oncology
Tumor Microenvironment We focus our efforts on a clearly defined scientific approach. Evolving Tumor Microenvironment Strategy Our evolving strategy centers on innovative approaches to drug development based on a deep understanding of the critical ...